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Novel Combination Strategies to Enhance Immune Checkpoint 
Inhibition in Cancer Immunotherapy: A Narrative Review  
Jonathan A. Hermel,1 Cassi M. Bruni,2 Darren S. Sigal.3 
Abstract 
Programmed cell death protein-1 (PD-1) is an immune checkpoint receptor that induces and maintains tolerance of T cells, invariant natural killer T (iNKT) 
cells, and natural killer (NK) cells, among other lymphocytes. Immune checkpoint inhibition by PD-1 blockade restores the lymphocytic immunostimulatory 
phenotype and has been successful in the treatment of various malignancies. However, while immune checkpoint blockade has been shown to provide 
robust antitumor treatment outcomes, its overall response rate remains low in a significant portion of cancer patients. An essential unmet need in cancer 
therapy is the development of novel pharmacologic strategies designed to lower rates of resistance associated with immune checkpoint blockade. 
Therefore, efforts that seek to enhance the efficacy of PD-1 inhibition possess profound immunotherapeutic potential. Here, three promising combination 
strategies that harness the antitumor effects of immune checkpoint inhibitors (ICIs) together with non-ICI antitumor therapeutic agents are reviewed. 
These agents include (1) ABX196, a potent inducer of iNKT cells, (2) chimeric antigen receptor (CAR)-T cell therapy, and (3) NK cell therapy. A comprehensive 
literature search was conducted using the PubMed and ClinicalTrials.gov databases for scientific articles and active trials, respectively, pertaining to 
immune checkpoint inhibition, iNKT cells, CAR-T cells, and NK cell immunotherapy. Preliminary clinical and preclinical data suggest that these combination 
treatment regimens greatly suppress tumor growth and may serve as innovative methods to enhance and optimize anticancer immunotherapy. 
 




Immunotherapy represents the newest pillar in anticancer therapy. The 
first fifty years of anticancer therapy consisted solely of cytotoxic 
chemotherapy, but this began to change in the 1990s with the advent 
of monoclonal antibodies and again in the early 2000s with the 
development of small molecule tyrosine kinase inhibitors. Each 
successive new approach has increased therapeutic efficacy and 
resulted in improved patient outcomes. United States Food and Drug 
Administration (FDA)-approved immunotherapies, in the form of 
immune checkpoint inhibitors (ICIs) to the cytotoxic T-lymphocyte-
associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-
1) checkpoint receptors, may represent the most profound advances in 
anticancer therapy in modern history. Cancers notoriously difficult to 
manage, including non-small cell lung cancer (NSCLC) and melanoma, 
have responded well to ICI immunotherapy, whether administered 
solely as monotherapy or in combination with chemotherapy in the 
neoadjuvant, adjuvant, and advanced late-stage settings.1,2,3 However, 
despite their proven antitumor treatment outcomes, ICIs have modest 
overall response rates, not only between varying cancer types, but also 
among patients who share the same malignancy.4 The identification of 
novel tumor biomarkers is an ongoing area of research aimed at 
predicting resistance to ICI immunotherapy and developing targeted 
approaches that seek to overcome this resistance.5 It remains that a 
key unmet need in cancer therapy is improving the consistency and 
functional efficacy of ICIs in a majority of cancer patients. A variety of 
novel immune therapies and targeting approaches are in clinical 
development that may mark another important step forward towards 
this goal. This review will examine the preclinical and clinical data of 
ABX196, a non-checkpoint inducer of invariant natural killer T (iNKT) 
cells; chimeric antigen receptor (CAR)-T cell therapy; and natural killer 




An extensive scientific literature search was performed using the 
PubMed database for peer-reviewed articles published in academic 
journals related to immune checkpoint inhibition, iNKT cells, CAR-T 
cells, and NK cells. The literature search was conducted between the 
months of May and July 2020. Search parameters included combinations 
of the keywords “ABX196,” “α-GalCer,” “invariant natural killer T cell,” 
“iNKT cell,” “chimeric antigen receptor T cell,” “CAR-T cell,” “natural 
killer cell,” or “NK cell,” with the terms “PD-1,” “immune checkpoint 
inhibitor,” “immune checkpoint inhibition,” or “immunotherapy.” Only 
studies published in English with full available text were screened for 
use. Because of the intended comprehensive nature of this review, a 
small portion of the manuscript pertaining to the background and 
history of α-GalCer mechanistic studies includes original articles 
published from 1994 to 2018. For the remainder of the paper, only 
articles published within the past 10 years were considered for use. 
Article abstracts were closely reviewed for applicability to the research 
question and those without clear relevance were removed from 
consideration. For information regarding active clinical trials, a detailed 
search of ClinicalTrials.gov was conducted. Initial search parameters 
included the keyword phrases, “ABX196,” “CAR-T cell,” “NK cell” or 
“natural killer cell.” Trials located in all countries were included for 
Review  
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review; however, trials that were not in the recruiting or pre-recruiting 
stages were filtered out. Listed trial titles and descriptions were then 
manually screened for protocols that included additional ICI 
immunotherapies. Trials that did not meet the aforementioned criteria 
were excluded. 
 
Results and Discussion 
ABX196 in Combination with PD-1 Blockade 
Background and rationale: iNKT cell anergy is associated with PD-1 
upregulation 
ABX196 is a synthetic glycolipid analogue of α-galactosylceramide (α-
GalCer), a strong agonist of invariant natural killer T (iNKT) cells. In 
contrast to conventional T and NK lymphocytes, iNKT cells induce both 
innate and adaptive antitumor immune responses.6 iNKT cells express 
an invariant T cell receptor (TCR) composed of Vα14-Jα18/Vβ8.2 gene 
chain rearrangements in mice and Vα24-Jα18/Vβ11 gene chain 
rearrangements in humans.7 These invariant TCRs recognize 
endogenous and exogenous lipid moieties bound to and presented on 
non-classical, major histocompatibility complex (MHC) class I-like CD1d 
molecules.8 CD1d is a membrane-bound cell surface glycoprotein 
expressed primarily by B lymphocytes, macrophages, and dendritic 
cells (DCs).9 When lipid moieties are presented within the hydrophobic 
binding-groove of CD1d, they interact with the iNKT TCR; this association 
stimulates iNKT cells, which in turn modulate the immune system.10 
Specifically, in vivo administration of α-GalCer in mice triggers iNKT cells 
to i) rapidly proliferate, ii) release a variety of cytokines, including IFN-
γ and IL-4, iii) cross-prime dendritic cells to release IL-12, and iv) slow 
tumor growth and prevent metastasis.11,12 Although α-GalCer is a 
powerful iNKT cell-stimulating antigen, its antitumor efficacy is 
restricted by the fact that α-GalCer-stimulated iNKT cells release 
cytokines with opposing immune system actions, specifically IFN-γ, 
which initiates an immunostimulatory T helper 1 (TH1) response, and 
IL-4, which initiates an immunoregulatory T helper 2 (TH2) response.13 
The favorable effect of iNKT cells in antitumor immunity is due, in large 
part, to IFN-γ production.14 ABX196 consists of an acetamide group 
linked to the galactosyl C6 of α-GalCer, and this structural modification 
has been shown to enhance the secretion of TH1 cytokines.15 As 
compared to α-GalCer, ABX196 produces high levels of systemic IFN-γ 
but significantly lower levels of IL-4, confirming a pro-inflammatory TH1 
skew in cytokine production.15  
 
While ABX196 induces a more potent immunostimulatory response 
beneficial for antitumor immunity, iNKT cell activation quickly leads to 
a long term unresponsive, anergic state for two primary reasons: one, 
the iNKT TCR becomes downregulated;16,17 and two, PD-1 receptors 
become upregulated at the surface of iNKT cells.18,19 PD-1 is a T cell 
checkpoint receptor that, when bound to its ligand PD-L1, functions to 
induce and maintain T cell tolerance (Figure 1).20 The FDA has approved 
a number of monoclonal antibodies that target and interfere with the 
PD-1/PD-L1 signaling pathway for use in cancer therapy.21 These include 
anti-PD-1 antibodies nivolumab, pembrolizumab, and cemiplimab, as 
well as anti-PD-L1 antibodies atezolizumab, avelumab, and 
durvalumab.21 The aforementioned ICIs have emerged in recent years 
as effective therapeutics for a variety of cancers due to their unique 
ability to block and reverse T cell anergy.22 These findings have led to 
the pharmaceutical approach of simultaneously administering both an 
iNKT cell agonist and an anti-PD-1 antibody to limit iNKT cell anergy and 
thus enhance antitumor immunity. 
 
Preclinical Data: iNKT Agonist with PD-1 Blockade 
Several preclinical studies have explored the immunotherapeutic 
potential of α-GalCer-mediated iNKT induction in combination with PD-
1 blockade. Parekh et al.19 demonstrated that antibody-mediated 
inhibition of PD-1/PD-L1 interactions at the time of α-GalCer treatment 
prevented the induction of iNKT cell anergy and enhanced the anti-
metastatic activity of α-GalCer in wild-type mouse models.  The same 
study showed that PD-1  deficient  mice  were  resistant  to  α-GalCer- 




Legend: Simplified illustration demonstrating the mechanism of immune checkpoint 
inhibition in cancer immunotherapy. Figure 1.A. shows the T cell programmed cell 
death protein-1 (PD-1) receptor interacting with the corresponding tumor programmed 
cell death protein-1 ligand (PD-L1) receptor, leading to T cell anergy and inactivity. This 
occurs despite appropriate antigen presentation on the major histocompatibility 
complex (MHC) and proper recognition by the T cell receptor (TCR). Figure 1.B. 
demonstrates the targeted interruption of the PD-1/PD-L1 interaction by a monoclonal 
antibody immune checkpoint inhibitor (ICI). This inhibition of PD-1/PD-L1 signaling 
promotes continued stimulation of the T cell to induce tumor cell death. 
 
induced iNKT cell anergy. Durgan et al. 23 performed similar experiments 
with murine melanoma models. In their study, PD-L1 deficient mice 
were administered DCs loaded with antigen and α-GalCer; these mice 
subsequently had a significant reduction in tumor size associated with 
increased trafficking of antigen-presenting cells (APCs) and CD8+ 
cytotoxic T cells to the sites of tumors.23 The importance of α-GalCer 
and PD-1 blockade on CD8+ T cell cytotoxic activity has been 
demonstrated by Bae et al.,24 who found that administration of an iNKT 
agonist in an anti-PD-1-resistant tumor model re-stimulated exhausted 
CD8+ T cells through the enhanced secretion of IL-2 and IL-12. They also 
observed a synergistic increase in the antitumor effect between α-
GalCer-loaded APCs and PD-1 blockade. Moreover, in vitro assays with 
human peripheral blood mononuclear cells (PBMCs) showed that the 
simultaneous co-administration of an anti-PD-L1 antibody and α-GalCer-
pulsed APCs enhanced both the direct cytotoxic and indirect TH1 
cytokine release functions of iNKT cells, enhancing their antitumor 
immunostimulatory functions.25 Lastly, preclinical studies in mice have 
confirmed the similarities between ABX196 and α-GalCer concerning in 
vitro and in vivo stimulation of iNKT cells.15 Toxicity reports from these 
same experiments suggested no considerable adverse effects of ABX196 
in mice and monkeys at the doses necessary for immune activation, 
although hepatic toxicity in the form of elevated transaminases was 
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Clinical Data: ABX196 and Nivolumab in the Treatment of Hepatocellular 
Carcinoma 
Clinical studies assessing the immunotherapeutic rationale of 
administering iNKT agonists in combination with ICIs are sparse and 
have only recently been initiated for the treatment of hepatocellular 
carcinoma (HCC). HCC nearly always develops secondary to chronic liver 
inflammation, as this produces an immunosuppressive microenvironment 
that accommodates immune cell exhaustion.26 Exhausted immune cells 
exist in an inactive anergic state, expressing high levels of inhibitory 
co-receptors, such as PD-1 and CTLA-4, and low levels of effector 
cytokines. As a result, anti-PD-1 antibodies have been studied in HCC 
and found to be an effective treatment.27 Nivolumab received FDA 
approval in September 2017 for patients with advanced HCC previously 
treated with the multi-kinase inhibitor sorafenib during the phase I/II 
dose-escalation and dose-expansion CheckMate-040 study.28 Nivolumab 
resulted in significant tumor diminution compared to first-line sorafenib 
therapy; however, its objective response rate (ORR) remained low at 
15% (95% CI 6-28) in the dose-escalation phase and 20% (95% CI 15-26) 
in the dose-expansion phase. This has prompted additional efforts to 
improve nivolumab response rates in HCC treatment, and the first open 
label, uncontrolled phase I/II clinical trial to assess combination therapy 
of ABX196 with nivolumab is now underway at the Scripps M.D. 
Anderson Cancer Center [NCT03897543]. Importantly, the trial addresses 
the question of whether the immunostimulatory effects of ABX196 may 
help bolster the efficacy of nivolumab immunotherapy in HCC by 
specifically targeting and reversing iNKT cell anergy. 
 
Since Hepatitis B infection is associated with increased risk of HCC, the 
adjuvant activity of ABX196 may play a critical role in HCC 
immunotherapeutic control. In a phase I first-in-human dose-escalation 
study, ABX196 induced a strong anti-HepB antibody response when 
used as an adjuvant for a prophylactic hepatitis B vaccine.15 In all forty-
four healthy male subjects treated, ABX196 elicited a stimulation of NKT 
cells in vivo as demonstrated by the downregulation of NKT TCR and 
pronounced antibody response. Adverse side effects were mild to 
moderate and associated with elevated IFN-γ levels, consistent with 
acute activation of hepatic iNKT cells by ABX196. Similarly, many clinical 
trials (Table 1) have tested the anticancer therapeutic potential of α-
GalCer in humans, and it has been shown to be a safe and well-
tolerated treatment plan, although its effectiveness in these trials was 
limited due to iNKT cell anergy and the development of 
immunosuppressive tumor microenvironments.42 
 
CAR-T Cells in Combination with PD-1 Blockade 
Background: The Therapeutic Evolution of CAR-T Cells 
Chimeric antigen receptor (CAR)-T cells are genetically modified T cells 
designed to express a synthetic TCR for use in anticancer 
immunotherapy. T cells are isolated from human blood and engineered 
to express a unique CAR. CAR-T cells are then stimulated to expand ex 
vivo and are infused back into the patient to kill tumor cells expressing 
the corresponding CAR-T cell antigen.43 CAR constructs are hybrid 
molecules consisting of three regions: i) the extracellular ectodomain, 
usually composed of a single chain variable fragment (scFv) obtained 
from a tumor antigen-reactive antibody, ii) the transmembrane domain 
to support CAR stability, and iii) the intracellular endodomain, 
composed of signaling peptides responsible for cell activation and co-
stimulation following tumor antigen recognition (Figure 2).44 CAR-T cells 
are separated into four generations based on the composition of their 
endodomains.45 First generation CARs contain a scFv attached to a CD3ζ-
derived intracellular signaling molecule, the primary transmitter of 
endogenous TCR stimulation. Second generation CARs contain an 
additional co-stimulatory molecule as part of the signal transduction 
region.46 Third generation CARs combine multiple intracellular co- 
stimulatory domains to increase cytokine production. Fourth generation 
CARs, also referred to as T cell redirected for universal cytokine-
mediated killing (TRUCKs), contain a transgenic load of immune 
modifiers, such as cytokines, co-stimulatory ligands and enzymes, that  
 
Table 1. Clinical Trials Evaluating α-GalCer-Mediated Stimulation of iNKT Cells 
 
Clinical trial No. of participants Treatment Result Cancer type(s) 
Giaccone et al.29 24 α-GalCer; intravenous 7 SD Solid tumors 
Nieda et al.30 12 α-GalCer-pulsed CD1d-expressing DCs; 
intravenous 
3 reductions in tumor 
markers/mass 
Solid tumors 
Ishikawa et al.31 11 enrolled, 
9 completed 
α-GalCer-pulsed DCs; intravenous 5 SD NSCLC 
Chang et al.32 6 enrolled, 
5 completed 
α-GalCer loaded onto monocyte-derived mature 
DCs; intravenous 
4 reductions in tumor markers 
or SD 
MM, RCC,  
Anal SCC 
Motohashi et al.33 6 α-GalCer-activated Vα24 iNKT cells; intravenous 4 SD NSCLC 
Uchida et al.34 9 α-GalCer-pulsed APCs; administered in nasal 
submucosa 
1 PR, 5 SD HNSCC 
Motohashi et al.35 23 enrolled, 
17 completed 
α-GalCer-pulsed PBMC cultured with IL-2 and GM-
CSF; intravenous 
5 SD NSCLC 
Kunii et al.36 8 Intra-arterial infusions of α-GalCer- activated 
Vα24 iNKT cells + submucosal injections of α-
GalCer-pulsed APCs 
3 PR, 4 SD HNSCC 
Kurosaki et al.37 17 α-GalCer-pulsed APC injections into nasal or oral 
floor submucosa 
Increased levels of iNKT 
cells/IFN-γ 
HNSCC 
Yamasaki et al.38 10 Nasal submucosal administration of α-GalCer-
pulsed APCs  
+ intra-arterial infusion of α-GalCer-activated 
iNKT cells via tumor-feeding arteries 
5 PR, 5 SD HNSCC 
Nicol et al.39 12 α-GalCer-pulsed DCs; 2 treatments intravenous, 2 
treatments intradermal 
3 PR, 3 SD Solid tumors 
Nagato et al.40 4 α-GalCer-pulsed APCs; intravenous Increased levels of iNKT cells in 
TILs, increased IFN-γ levels 
NSCLC 
Richter et al.41 6 α-GalCer-loaded monocyte-derived DCs + low-
dose lenalidomide; intravenous 





Abbreviations: SD, stable disease; PR, partial remission; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; MM, multiple myeloma; RCC, renal 
cell carcinoma; SCC, squamous cell carcinoma; DC, dendritic cell; APC, antigen presenting cell; TIL, tumor infiltrating lymphocyte. 
Review  
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upon release help activate and recruit innate immune cells to eliminate 
antigen-negative tumor cells.47 TRUCKs enhance antitumoral activity 
through inducible IL-12, creating an immunostimulatory tumor 
microenvironment and favorably redirecting host lymphocytes toward 
the tumor site.48 
 




Legend: Simplified diagram of the chimeric antigen receptor (CAR)-T cell structure. The 
extracellular ectodomain communicates with a specific tumor cell antigen via the single chain 
variable fragment (scFv), which is derived from an antibody that reacts with a given tumor 
antigen. The transmembrane domain provides stability to the CAR structure. The endodomain 
is responsible for communicating intracellular signals that promote T cell activation. 
 
Rationale for CAR-T Cell Combination Therapy with ICIs 
While conventional CAR-T cell therapy has demonstrated clinical 
success against B cell hematologic malignancies,49,50 its efficacy is 
limited by several important obstacles, including high toxicity, 
immunosuppressive tumor milieu, and CAR-T cell dysfunction.51 One of 
the primary reasons for poor treatment response and relapse after CAR-
T cell therapy is inefficient T cell expansion and a lack of persistent T 
cell activation following infusion of CAR-T cells into patients.44 It is 
thought that CAR-T cell dysfunction and non-persistence is driven by 
co-inhibitory pathways induced by checkpoint blockade that lead to T 
cell anergy.52 CAR-T cells were shown to upregulate immune checkpoint 
receptors, such as PD-1, CTLA-4 and lymphocyte activating gene-3 (LAG-
3), in patients with chronic lymphocytic leukemia (CLL) unresponsive 
to anti-CD19 CAR-T cell therapy.53 CLL is a hematologic malignancy with 
particularly poor response rates to CAR-T cell therapy and is known to 
facilitate an immunosuppressive, pro-tumor microenvironment.54 PD-
L1 expression was found to be significantly higher in 112 CLL patients 
than in non-CLL controls.55 Similarly, mesothelin-specific CAR TILs 
(tumor-infiltrating lymphocytes) administered to mice bearing human 
mesothelin-expressing flank tumors underwent rapid and spontaneous 
loss of functional activity associated with increased expression of the 
surface inhibitory receptors PD-1, LAG3, T cell immunoglobulin- and 
mucin-domain-containing molecule 3 (TIM3) and 2B4 (CD244).56 The 
aberrant expression of inhibitory molecules has been demonstrated in 
CAR-T cell clinical trials as well.57 Infusion of anti-CD19 CAR-T cells to 
patients with advanced B cell lymphomas resulted in at least three-fold 
increase in expression of PD-1 at the surfaces of CD4+ CAR-positive cells 
in 8 out of 11 patients.57 These studies suggest that checkpoint-based 
immunosuppression is an important mechanism mediating tumor 
resistance to CAR-T cell therapy. Therefore, strategies that block 
inhibitory immune checkpoint pathways in combination with CAR-T cell 
therapy possess powerful immunotherapeutic potential.  
 
Preclinical Data: CAR-T Cells with PD-1 Blockade 
CAR-T cell combination therapy with PD-1 blockade has demonstrated 
improved antitumor effects in multiple preclinical models. In adoptive 
transfer studies of mice bearing human epidermal growth factor 
receptor-2 (HER-2)+ tumors, anti-PD-1 antibodies enhanced HER-2-
specific CAR-T cell functionality, significantly increased markers of 
activation and proliferation, improved tumor growth inhibition, and 
reduced the percentage of myeloid-derived suppressor cells, which – 
when produced in excess – are known to aid in tumor metastasis and 
immune evasion.58 Similarly, PD-L1 inhibition in mouse CLL models 
reactivated immune effector functions and restored cytotoxic CD8+ T cell 
activity as well as immune synapse formation ex vivo and in vivo by 
preventing exhaustion-like T cell phenotypes.59 Experiments conducted 
with an orthotopic mouse model of pleural mesothelioma showed that 
PD-1 pathway interference restored the effector function of exhausted 
CD28-specific CAR-T cells.60 Gargett et al.61 demonstrated that third 
generation GD2-specific CAR-T cells would undergo significant 
activation-induced cell death (AICD) after repeated antigen stimulation 
in vitro; however, PD-1 blockade enhanced both CAR-T cell survival and 
promoted killing of PD-L1+ tumor cell lines.  CRISPR-Cas9-mediated 
editing of CAR-T cells, which rendered them non-responsive to PD-1 
signaling, improved antitumor CAR-T cell activity both in vitro and in 
vivo.62 Finally, Hui et al. 63 showed that PD-1/PD-L1 interactions 
suppressed CAR-T cell activity by blocking CD28 signaling, suggesting 
that upregulation of costimulatory pathways is an important 
mechanistic response of CAR-T cells to anti-PD-1/PD-L1 therapy. 
 
Clinical Data: CAR-T Cells with PD-1 Blockade 
Clinical trials employing CAR-T cell combination therapy with PD-1 
blockade have already shown promising results. In a single-institution 
study at the Children’s Hospital of Philadelphia, fourteen pediatric 
patients with heavily treated, relapse B cell acute lymphoblastic 
leukemia (B-ALL) and poor responses to CAR-T cell therapy were treated 
with CD19-specific CAR-T cell therapy in combination with an anti-PD-1 
monoclonal antibody.64 Encouraging results were particularly observed 
in patients with early B-cell recovery and bulky extramedullary disease. 
Three of 6 patients treated with PD-1 inhibitor and CAR-T cells for early 
B cell recovery reestablished B cell aplasia, an indication of persistent 
CAR-T cell activation. In a cohort of four patients treated with 
pembrolizumab and CAR-T cells for extramedullary disease, 2 partial 
remissions (PRs) and 2 complete remissions (CRs) were seen. However, 
in the 4 remaining patients who were unsuccessful in achieving 
remission with initial CAR-T cell therapy, only PRs were observed with 
CAR-T cell and pembrolizumab combination therapy. Adverse effects of 
combination therapy included fever, acute pancreatitis, 
hypothyroidism, joint pains, as well as moderate to severe 
pancytopenia. The study supports the hypotheses that upregulation of 
the PD-1/PD-L1 signaling axis may be a driving force in the development 
of resistance to CAR-T cell immunotherapy. The study also suggests that 
ICI combination therapy at the time of CAR-T cell administration may 
be a safe and durable strategy for preventing subsequent AICD in the 
treatment of B-ALL.  
 
A similar single-institution trial at the Abramson Cancer Center of the 
University of Pennsylvania attempted to evaluate the role of 
pembrolizumab as salvage therapy for patients who experienced 
worsening disease following initial CAR-T cell infusion.65 The study 
enrolled 12 patients with progressive or relapse B cell non-Hodgkin 
lymphomas with partial or no response to CD19-specific CAR-T cell 
therapy. Pembrolizumab was administered to these patients every 3 
weeks until disease progression or adverse toxic side effects were 
observed. The addition of PD-1 blockade after prior ineffective anti-CD19 
CAR-T cell therapy produced an ORR of 27% (1 CR and 2 PRs), including 
1 patient with stable disease and 7 patients with progressive disease. 
Nine of 12 patients demonstrated a re-expansion of peripheral blood 
CAR-T cells after the first pembrolizumab dose, although this cellular 
re-expansion did not correlate with clinical outcome. Nevertheless, this 
study highlights the key theory that ICIs may reinvigorate exhausted 
CAR-T cells in patients with poor or failed responses to initial CAR-T cell 
therapy, and further studies should be explored to translate this CAR-T 
cell re-expansion into clinically efficacious use. At the moment, several 
clinical trials (Table 2) are attempting to address the optimal timing of 
administration, dosing, efficacy, and safety of CAR-T cell combination 
therapy with ICIs, particularly  in  patients  who  have  failed  first-line 
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CAR-T ICI Cancer type(s) 
NCT03310619 Celgene/PLATFORM 100 JCAR017 Durvalumab NHL, DLBCL, FL 
NCT03287817 Autolus Limited/ALEXANDER 120 AUTO3 Pembrolizumab DLBCL 
NCT02706405 Fred Hutchinson Cancer Research Center 42 JCAR014 Durvalumab 
NHLs + gene 
rearrangement(s), 
DLBCL, PMBL 
NCT03630159 Novartis Pharmaceuticals/ PORTIA 32 CTL019 Pembrolizumab DLBCL 
NCT02926833 Kite, A Gilead Company/ZUMA-6 37 KTE-C19 Atezolizumab DLBCL 
NCT03726515 University of Pennsylvania 7 CART-EGFRvIII Pembrolizumab Glioblastoma 
NCT04003649 City of Hope Medical Center 60 IL13Ralpha2-CRT T cells Ipilimumab, nivolumab Glioblastoma 
NCT03525782 
The First Affiliated Hospital of 
Guangdong Pharmaceutical University 
60 Anti-MUC1 CAR-T cells Nivolumab NSCLC 
NCT02414269 Memorial Sloan Kettering Cancer Center 66 iCasp9M28z, T cells Pembrolizumab 
Lung/breast cancers, 
mesotheliom 
Legend: NHL, non-Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; PMBL, primary mediastinal B cell lymphoma; NSCLC, non-small cell lung cancer 
 
trials address ICI and CAR-T cell combination therapy in two primary 
treatment scenarios: 1) when the agents are administered 
simultaneously, or 2) when the ICI is administered for a limited duration 
shortly after CAR-T cell infusion. Taken together, these studies attempt 
to assess both the potential of concurrent ICI and CAR-T cell therapy to 
prevent the development of future AICD as well as the salvage potential 
of ICIs to enhance prior ineffective CAR-T cell therapy. Investigating ICI 
and CAR-T cell combination therapy from both of these angles may 
provide a better understanding of the appropriate timeframe in which ICIs 
can most effectively enhance and prevent resistance to CAR-T cell therapy. 
 
NK Cells in Combination with PD-1 Blockade 
Applications, Advantages, and Challenges of NK Cell Therapy 
Natural killer (NK) cells are cytotoxic innate lymphoid cells that play a 
vital role in antitumor immunity due to their unique ability to detect 
and eliminate malignant cells with downregulated surface expression 
of self-MHC-I molecules.66 NK cell functions vary widely and include 
degranulation, cytokine secretion primarily in the form of IFN-γ, and 
direct cytotoxicity due to an elaborate interaction of inhibitory and 
activating signals.67 Many antitumor therapeutic strategies have 
emerged in recent years that utilize the cytotoxic and 
immunoregulatory activities of NK cells. Adoptive transfer therapy, in 
which NK cells from a healthy donor are isolated, activated ex vivo in 
an IL-2 or IL-15 solution, then infused into cancer patients, has proven 
to be an effective and nontoxic antitumor treatment.68 More recently, 
isolated NK cells have been genetically modified to express a unique 
tumor-antigen CAR prior to re-infusion. CD19- and CD20-specific CAR-NK 
cells have shown successful preclinical tumor growth inhibition in a 
variety of B cell malignancies.69 CAR-NK cells targeting HER-2, epidermal 
growth factor receptor (EGFR), natural killer group 2D (NKG2D), and 
disialoganglioside GD2 receptors, all of which are overexpressed in 
tumor cells, have also shown preclinical antitumor efficacy against solid 
tumors.69 CAR-NK cell therapy has advantages over CAR-T cell therapy 
in that it does not induce graft versus host disease (GVHD),70,71 nor does 
the CAR modification prevent the NK cell from carrying out its non-
specific innate functions, thus limiting the occurrence of antigen loss 
and tumor escape.72 In addition, CAR-NK cell therapy eliminates the 
need for a personalized, autologous product typically required with 
CAR-T cell therapy. CAR-NK cell therapy, therefore, has the potential to 
be an affordable and readily available, “off-the-shelf” treatment option. 
The aforementioned therapeutic benefits are limited in part by the 
ability of injected NK cells to migrate to tumor sites, persist, and expand 
in vivo.73 NK cells express a range of inhibitory receptors, including PD-
1, PD-L1, CTLA-4, T cell immunoglobulin and mucin-containing protein 3 
(TIM3), T cell immunoreceptor with immunoglobulin and 
immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), LAG-3, 
interleukin-1 receptor 8 (IL-1R8), and CD96, in addition to more well-
established inhibitory receptors, like killer-cell immunoglobulin-like 
receptor (KIR) and the C-type lectin inhibitory receptor CD94/natural 
killer group 2A (NKG2A).74,75 Research into the blockade of these 
inhibitory NK cell immune checkpoint pathways is ongoing and early 
data reflect an encouraging possibility of immune checkpoint inhibition 
to overcome the immunosuppressive limitations currently associated 
with NK cell therapy.76 For the purposes of this review, literature 
pertaining specifically to inhibition of the PD-1/PD-L1 axis was the focus. 
 
Rationale for Combining NK Cell Therapy with PD-1 Blockade  
PD-1 is highly expressed on a distinct subpopulation of NK cells with 
impaired immunostimulatory capabilities that are detectable in 
approximately 25% of healthy people.77 NK cell populations with high 
PD-1 expression demonstrate significantly reduced function and are 
found in greater proportion in patients with ovarian carcinoma,77 Kaposi 
sarcoma,78 multiple myeloma,79 and head and neck cancers.80 In vitro 
studies have confirmed that PD-1 receptors become upregulated at the 
surface of healthy control NK cells upon extended contact with 
activating ligands,78 suggesting that PD-1 helps induce, as it does for T 
lymphocytes, NK cell anergy. This increased expression of PD-1 at the 
surface of NK cells correlates with poorer survival prognosis in 
esophageal and liver cancers.81 More recent studies have determined 
that upregulated PD-L1 expression at the surface of NK cells also 
mediates exhaustive NK phenotypes. Dong et al., 75 for instance, 
discovered that some tumors can induce PD-L1 expression on NK cells 
via protein kinase B (AKT) signaling.  These discoveries support the idea 
that NK cells are a valuable target in immunotherapeutic approaches 
that inhibit PD-1/PD-L1 interactions, especially when these ICIs are used 
to treat tumors that are MHC-I deficient. Thus, utilizing PD-1 blockade 
may be an excellent additive strategy for immunotherapy regimens that 
harness the antitumor capabilities of NK cells. 
 
Preclinical data: NK cells with PD-1 blockade 
Preclinical studies have shown that inhibiting PD-1 and PD-L1 
checkpoint receptors enhances the immunotherapeutic efficacy of NK 
cells. Benson et al.79 demonstrated that a PD-1 blocking antibody 
improved human NK cell functionality against autologous, primary 
multiple myeloma cells in vitro through a mechanism involving NK cell 
trafficking, immune complex formation, and enhanced cytotoxicity 
directed toward PD-L1+ tumor cells.  Blocking PD-1/PD-L1 signaling 
notably enhanced cytokine secretion and inhibited NK cell apoptosis in 
vitro. Importantly, administration of an anti-PD-1 antibody significantly 
slowed tumor growth in HCC xenografts, and this beneficial antitumor 
response was diminished by NK cell depletion, indicating an NK-
dependent antitumor mechanism in response to PD-1 blockade.81 Hsu 
et al. 82 performed similar experiments on several mouse models of 
cancer, including lymphoma, melanoma, prostate adenocarcinoma, and 
colon carcinoma, and determined that the release of PD-1-imposed 
inhibition activated an NK response that was indispensable for the full 
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effect of ICI immunotherapy. Oyer et al. 83 observed a significant 
improvement in NK cell antitumor efficacy, persistence, and retention 
of cytotoxic activity in mouse ovarian cancer models when combined 
with anti-PD-L1 antibody. The group showed that expanded NK cells 
secreted large amounts of IFN-γ, which induced expression of PD-L1 on 
human ovarian cancer cells in vivo. These findings support NK cell 
combination therapy with anti-PD-L1 antibody, irrespective of initial 
tumor PD-L1 status. Lastly, Dong et al. 75 determined that various PD-L1- 
tumor cell lines still responded favorably to anti-PD-L1 monoclonal 
antibody therapy, because the anti-PD-L1 antibody directly targeted and 
activated PD-L1+ NK cells in a PD-1 independent process.  
 
Clinical Data: NK Cells with PD-1 Blockade 
While preclinical data has confirmed the immunostimulatory advantage 
of PD-1 blockade on NK cell functionality, clinical trials are new and in 
their early stages. A phase II study assessing the effects of 
pembrolizumab on NK cell exhaustion in patients with malignant 
melanoma was recently terminated due to enrollment difficulties 
[NCT03241927]. Nevertheless, several clinical trials (Table 3) evaluating 
the therapeutic benefit of PD-1 blockade on NK cell antitumor activity 
are currently underway. 
 
Conclusion 
Immunotherapy continues to revolutionize cancer treatment in the 
twenty-first century. ABX196, CAR-T cell and NK cell immunotherapies, 
in particular, have shown compelling preclinical data and are in early 
phase studies to determine if this activity can be translated into patient 
care. These therapeutics have mechanisms of action that are distinct 
from approved ICIs, which may overcome some of the limitations that 
have plagued ICI immunotherapy. Modulating multiple levers of the 
immune system simultaneously by co-administering ICIs with either 
ABX196, CAR-T cells or NK cells may further the essential, as-yet unmet, 
goal of overcoming tumor resistance to ICI immunotherapy. While 
awaiting the results of these agents’ early clinical trials, additional 
studies should be pursued to both enhance and optimize these 
promising new immunotherapy approaches. 
 
















Sintilimab (anti-PD-1) + 
NK cells (autologous NK 






























1. Madden K, Kasler MK. Immune Checkpoint Inhibitors in Lung Cancer and 
Melanoma. Semin Oncol Nurs. 2019 Oct;35(5):150932. 
2. Herrscher H, Robert C. Immune checkpoint inhibitors in melanoma in the 
metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol. 2020 
Mar;32(2):106-13. 
3. Ren S, Wang C, Shen J, Zhu C. Neoadjuvant immunotherapy with resectable non-
small cell lung cancer: recent advances and future challenges. J Thorac Dis. 2020 
Apr;12(4):1615-20. 
4. Sambi M, Bagheri L, Szewczuk MR. Current Challenges in Cancer Immunotherapy: 
Multimodal Approaches to Improve Efficacy and Patient Response Rates. J Oncol. 
2019 Feb 28;2019:4508794. 
5. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for 
checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019 Mar;19(3):133-50. 
6. Nair S, Dhodapkar MV. Natural Killer T Cells in Cancer Immunotherapy. Front 
Immunol. 2017 Sep 22;8:1178. 
7. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique 
subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T 
cells in mice and humans. J Exp Med. 1994 Sep 1;180(3):1097-106. 
8. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 
recognition by mouse NK1+ T lymphocytes. Science. 1995 May 12;268(5212):863-5. 
9. Zajonc DM, Kronenberg M. CD1 mediated T cell recognition of glycolipids. Curr 
Opin Struct Biol. 2007 Oct;17(5):521-9.  
10. Kronenberg, M. Toward an understanding of NKT cell biology: progress and 
paradoxes. Annu Rev Immunol. 2005;23:877-900. 
11. McEwen-Smith, RM, Salio M, Cerundolo V. The regulatory role of invariant NKT 
cells in tumor immunity. Cancer Immunol Res. 2015 May;3(5):425-35. 
12. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, et al. 
Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin 
Invest. 2005 Sep;115(9):2572-83. 
13. Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M, et al. Mouse V 
alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc 
Natl Acad Sci USA. 2003 July 8;100(14):8395-400. 
14. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells - 
conductors of tumor immunity? Curr Opin Immunol. 2002 Apr;14(2):165-71. 
15. Tefit JN, Crabe S, Orlandini B, Nell H, Bendelac A, Deng S, et al. Efficacy of ABX196, 
a new NKT agonist, in prophylactic human vaccination. Vaccine. 2014 Oct 
21;32(46):6138-45. 
16. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, et al. 
Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin 
Invest. 2005 Sep;115(9):2572-83. 
17. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, et 
al. The response of natural killer T cells to glycolipid antigens is characterized 
by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA. 
2003 Sep 16;100(19):10913-8. 
18. Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, et al. Cutting edge: 
Programmed death-1/programmed death ligand 1 interaction regulates the 
induction and maintenance of invariant NKT cell anergy. J Immunol. 2008 Nov 
15;181(10):6707-10. 
19. Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, et al. PD-1/PD-L blockade 
prevents anergy induction and enhances the anti-tumor activities of glycolipid-
activated invariant NKT cells. J Immunol. 2009 Mar 1;182(5):2816-26. 
20. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and 
immunity. Annu Rev Immunol. 2008;26:677-704. 
21. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications 
of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the 
Level of Evidence. Cancers (Basel). 2020 Mar 20;12(3):738. 
22. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-
L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, 
Combinations, and Clinical Outcome. Front Pharmacol. 2017 Aug 23;8:561. 
23. Durgan K, Ali M, Warner P, Latchman YE. Targeting NKT cells and PD-L1 pathway 
results in augmented anti-tumor responses in a melanoma model. Cancer 
Immunol Immunother. 2011 Apr;60(4):547-58. 
24. Bae EA, Seo H, Kim BS, Choi J, Jeon I, Shin KS, et al. Activation of NKT Cells in an 
Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by 




Hermel JA, et al. Novel Combination Strategies to Enhance Immune Checkpoint 
Inhibition in Cancer Immunotherapy: A Narrative Review
 
 
Int J Med Students   •   2020  |  Sep-Dec  |  Vol  8  |  Issue 3 
                             DOI 10.5195/ijms.2020.753  |  ijms.info The International Journal of Medical Students 279
 
25. Kamata T, Suzuki A, Mise N, Ihara F, Takami M, Makita Y, et al. Blockade of 
programmed death-1/programmed death ligand pathway enhances the 
antitumor immunity of human invariant natural killer T cells. Cancer Immunol 
Immunother. 2016 Dec;65(12):1477-89. 
26. Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: 
Primed to make a difference? Cancer. 2016 Feb 1;122(3):367-77. 
27. Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, et al. Immune-based 
therapies for hepatocellular carcinoma. Oncogene. 2020 Apr;39(18):3620-37. 
28. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in 
patients with advanced hepatocellular carcinoma (CheckMate 040): an open-
label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 
2017 Jun 24;389(10088):2492-502. 
29. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study 
of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients 
with solid tumors. Clin Cancer Res. 2002 Dec;8(12):3702-9. 
30. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic 
activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly 
coordinated secondary activation of acquired and innate immunity. Blood. 2004 
Jan 15;103(2):383-9. 
31. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A 
phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in 
patients with advanced and recurrent non-small cell lung cancer. Clin Cancer 
Res. 2005 Mar 1;11(5):1910-7. 
32. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained 
expansion of NKT cells and antigen-specific T cells after injection of alpha-
galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 
2005 May 2;201(9):1503-17. 
33. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, et al. A phase 
I study of in vitro expanded natural killer T cells in patients with advanced and 
recurrent non-small cell lung cancer. Clin Cancer Res. 2006 Oct 15;12,(20 Pt 
1):6079-86. 
34. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, et al. Phase 
I study of alpha-galactosylceramide-pulsed antigen presenting cells 
administration to the nasal submucosa in unresectable or recurrent head and 
neck cancer. Cancer Immunol Immunother. 2008 Mar;57(3):337-45. 
35. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase 
I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral 
blood mononuclear cells in patients with advanced and recurrent non-small cell 
lung cancer. J Immunol. 2009 Feb 15;182(4):2492-501. 
36. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, et al. 
Combination therapy of in vitro-expanded natural killer T cells and alpha-
galactosylceramide-pulsed antigen-presenting cells in patients with recurrent 
head and neck carcinoma. Cancer Sci. 2009 Jun;100(6):1092-8. 
37. Kurosaki M, Horiguchi S, Yamasaki K, Uchida Y, Motohashi S, Nakayama T, et al. 
Migration and immunological reaction after the administration of alphaGalCer-
pulsed antigen-presenting cells into the submucosa of patients with head and 
neck cancer. Cancer Immunol Immunother. 2011 Feb;60(2):207-15. 
38. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, et al. 
Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-
targeted adoptive immunotherapy. Clin Immunol. 2011 Mar;138(3):255-65. 
39. Nicol AJ, Tazbirkova A, Nieda M. Comparison of clinical and immunological effects 
of intravenous and intradermal administration of alpha-galactosylceramide 
(KRN7000)-pulsed dendritic cells. Clin Cancer Res. 2011 Aug 1;17(15):5140-51. 
40. Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, et al. 
Accumulation of activated invariant natural killer T cells in the tumor 
microenvironment after alpha-galactosylceramide-pulsed antigen presenting 
cells. J Clin Immunol. 2012 Oct;32(5):1071-81. 
41. Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, et al. Clinical 
regressions and broad immune activation following combination therapy 
targeting human NKT cells in myeloma. Blood. 2013 Jan 17;121(3):423-30. 
42. Zhang Y, Springfield R, Chen S, Li X, Feng X, Moshirian R, et al. α-GalCer and iNKT 
Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials. Front 
Immunol. 2019 Jun 6;10:1126. 
43. Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. 
Lancet Oncol. 2020 Mar;21(3):e168-78. 
44. Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade 
and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019 Jun 
11;12 (1):59. 
45. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017 Jun 
24;5:22. 
46. Guedan S,  Posey AD, Jr,  Shaw C,  Wing A,  Da T,  Patel PR, et al. Enhancing CAR 
T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018 Jan 
11;3(1):e96976. 
47. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin 
Biol Ther. 2015 May;15(8):1145-54. 
48. Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T Cells 
Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through 
Induction of Host Immunity. Mol Ther Oncolytics. 2018 Mar 30;8:41-51. 
49. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-
term safety and activity of axicabtagene ciloleucel in refractory large B-cell 
lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 
2019 Jan;20(1):31-42. 
50. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. 
Investigators, J., Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large 
B-Cell Lymphoma. N Engl J Med. 2019 Jan 3;380(1):45-56. 
51. D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long 
and winding road to solid tumors. Cell Death Dis. 2018 Feb 15;9(3):282. 
52. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. 
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor 
efficacy in vivo. Nat Biotechnol. 2018 Oct;36(9):847-56. 
53. Galon J, Rossi J, Turcan S, Danan C, Locke FL, Neelapu SS, et al. Characterization 
of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor 
microenvironment immune gene profile in a multicenter trial (ZUMA-1) with 
axicabtagene ciloleucel (axi-cel, KTE-C19). J Clin Oncol. 2017 May 30;35(Suppl 
15):3025. 
54. Bair SM, Porter DL. Accelerating chimeric antigen receptor therapy in chronic 
lymphocytic leukemia: The development and challenges of chimeric antigen 
receptor T-cell therapy for chronic lymphocytic leukemia. Am J Hematol. 2019 
May;94(S1):S10-7. 
55. Grzywnowicz M, Karczmarczyk A, Skorka K, Zajac M, Zaleska J, Chocholska S, et 
al. Expression of Programmed Death 1 Ligand in Different Compartments of 
Chronic Lymphocytic Leukemia. Acta Haematol. 2015 Nov;134(4):255-62. 
56. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial 
T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen 
receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014 Aug 
15;20(16):4262-73. 
57. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-
Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and 
indolent B-cell malignancies can be effectively treated with autologous T cells 
expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 
20;33(6):540-9. 
58. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 
antibody therapy potently enhances the eradication of established tumors by 
gene-modified T cells. Clin Cancer Res. 2013 Oct 15;19(20):5636-46. 
Review  
 
Hermel JA, et al. Novel Combination Strategies to Enhance Immune Checkpoint 
Inhibition in Cancer Immunotherapy: A Narrative Review
 
 
Int J Med Students   •   2020  |  Sep-Dec  |  Vol  8  |  Issue 3 
                             DOI 10.5195/ijms.2020.753  |  ijms.info The International Journal of Medical Students 280
 
59. McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, et al. PD-L1 
checkpoint blockade prevents immune dysfunction and leukemia development 
in a mouse model of chronic lymphocytic leukemia. Blood. 2015 July 
9;126(2):203-11. 
60. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. 
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-
mediated inhibition. J Clin Invest. 2016 Aug 1;126(8):3130-44. 
61. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR 
T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but 
can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 
2016 Mar;24(6):1135-49. 
62. Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, et al. CRISPR-Cas9-mediated 
multiplex gene editing in CAR-T cells. Cell Res. 2017 Jan;27(1):154-7. 
63. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory 
receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017 Mar 
31;355(6332):1428-33.  
64. Li AM, Hucks GE, Dinofia AM, Seif AE, Teachey DT, Baniewicz D, et al. Checkpoint 
Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell 
Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood. 2018 Nov 
29;132(Suppl 1):556. 
65. Chong EA, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Winchell N, Napier E, et al. 
Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy 
(CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or 
Refractory B-Cell Non-Hodgkin Lymphomas. Blood. 2018 Nov 29;132(Suppl 
1):4198. 
66. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, 
Maturation, and Clinical Utilization. Front Immunol. 2018 Aug 13;9:1869. 
67. Paul S, Lal G. The Molecular Mechanism of Natural Killer Cells Function and Its 
Importance in Cancer Immunotherapy. Front Immunol. 2017 Sep 13;8:1124. 
68. Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current 
landscape. Virchows Arch. 2019 Apr;474(4):449-61. 
69. Rezvani K, Rouce R, Liu E, Shpall E. Engineering Natural Killer Cells for Cancer 
Immunotherapy. Mol Ther. 2017 Aug 2;25(8):1769-81. 
70. Locatelli F, Moretta F, Brescia L, Merli P. Natural killer cells in the treatment of 
high-risk leukemia. Semin Immunol. 2014 Apr;26(2):173–9. 
71. Rezvani K, Rouce RH. The Application of Natural Killer Cell Immunotherapy for 
the Treatment of Cancer. Front Immunol. 2015 Nov 17;6:578. 
72. Mehta RS, Rezvani K. Chimeric Antigen Receptor Expressing Natural Killer Cells 
for the Immunotherapy of Cancer. Front Immunol. 2018 Feb 15;9:283. 
73. Gras Navarro A, Bjorklund AT, Chekenya M. Therapeutic potential and challenges 
of natural killer cells in treatment of solid tumors. Front Immunol. 2015 Apr 
29;6:202. 
74. Kwon HJ, Kim N, Kim HS. Molecular checkpoints controlling natural killer cell 
activation and their modulation for cancer immunotherapy. Exp Mol Med. 2017 
Mar 31;49(3):e311. 
75. Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, et al. The mechanism of anti-PD-
L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing 
PD-L1 as a cytolytic effector. Cancer Discov. 2019 Oct;9(10):1422-37. 
76. Khan M, Arooj S, Wang H. NK Cell-Based Immune Checkpoint Inhibition. Front 
Immunol. 2020 Feb 13;11:167. 
77. Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. 
Identification of a subset of human natural killer cells expressing high levels of 
programmed death 1: A phenotypic and functional characterization. J Allergy Clin 
Immunol. 2017 Jan;139(1):335-6.e3. 
78. Beldi-Ferchiou A, Lambert M, Dogniaux S, Vely F, Vivier E, Olive D, et al. PD-1 
mediates functional exhaustion of activated NK cells in patients with Kaposi 
sarcoma. Oncotarget. 2016 Nov 8;7(45):72961-77. 
79. Benson DM, Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. 
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma 
effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. 
Blood. 2010 Sep 30;116(13):2286-94. 
80. Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 
Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer 
Patients. Cancer Immunol Res. 2018 Dec;6(12):1548-60. 
81. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li, C, et al. Increased expression of 
programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-
tumor function and indicates poor prognosis in digestive cancers. Oncogene. 
2017 Nov 2;36(44):6143-53. 
82. Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et 
al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. 
J Clin Invest. 2018 Oct 1;128(10):4654-68. 
83. Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor 




Conflict of Interest Statement & Funding  
Darren S. Sigal is an advisor for Celularity, Molecular Stethoscope, Curematch, and DrugCendR, has a patent on a method of use of TRK inhibitors in 
neuroendocrine tumors, and is on the speaker bureau for Celgene and Bayer. Jonathan A. Hermel and Cassi M. Bruni have no conflicts to declare. This 
research received no external funding. 
Author Contributions  
Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation: JAH, DSS. 
Visualization: JAH, DSS, CMB. Writing – Original Draft Preparation: JAH, DSS, Writing – Review & Editing: JAH, DSS, CMB.  
Cite as:  
Hermel JA, Bruni CM, Sigal DS. Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review. Int 
J Med Students. 2020 Sep-Dec;8(3):273-80. 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
ISSN 2076-6327 
This journal is published by the University Library System, University of Pittsburgh as part of the  
Digital Publishing Program and is co-sponsored by the University of Pittsburgh Press. 
 
